Navigation Links
UC Santa Barbara and Burnham Institute for Medical Research announce director
Date:8/10/2009

(La Jolla and Santa Barbara, Calif.) The Burnham Institute for Medical Research and the University of California, Santa Barbara have named leading biomedical researcher Jamey D. Marth director of a new joint Center for Nanomedicine that will be established at UCSB.

The collaborative biomedical research partnership merges UCSB's core expertise in engineering, materials sciences, nanotechnology, and physics with Burnham's strengths in the biological sciences and biomedical research. The new center will promote the convergence of these fields and pioneer the development of novel technologies for advancing human health. Together, UCSB and Burnham plan to recruit additional scientists to the Center for Nanomedicine to create collaborative research teams that will produce innovative technologies for an entirely new generation of biosensors, medical devices, drug delivery nanoparticles, instruments for advanced biomedical research, and other products.

Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve.

"Interdisciplinary nanotechnologies are vital to establishing a holistic and rigorous approach to biomedical research that encompasses disparate knowledge and integrates all of the cellular molecules and factors that contribute to disease," said Marth, who joined UCSB's faculty in the Department of Molecular, Cellular, and Developmental Biology (MCDB), as well as Burnham's faculty, on July 1.

At UCSB, Marth has been appointed to two prestigious endowed professorships. He is the first recipient of both the John Carbon Chair in Biochemistry and Molecular Biology and the Duncan and Suzanne Mellichamp Chair in Systems Biology in the campus's Biomolecular Science and Engineering Program. Prior to joining Burnham and UCSB, Marth was professor of cellular and molecular medicine and Howard Hughes Medical Institute Investigator at the UC San Diego School of Medicine.

"With appointments to both UCSB and Burnham, I look forward to building further bridges between the talented scientists at these institutions and to promoting our joint efforts to develop nanotechnologies for disease diagnosis, prevention, therapy, and cure," said Marth. "This new and timely initiative will require the expertise of engineers, physicists, bioinformatics experts, and materials scientists working in close collaboration with biologists, that builds on the complementary expertise that exists at UCSB and the Burnham Institute for Medical Research."

Marth's laboratory is world-renowned in the application of cellular biology to uncovering the origins of disease. Marth is engaged in collaborative projects with UCSB and Burnham Institute scientists to develop nanotechnology platforms for biomedical research, including the means to rapidly detect and manipulate the cellular components that are responsible for health and disease. His highly interdisciplinary research has led to the discovery of disease mechanisms that span multiple fields, including autoimmune disease, infectious disease, and dietary-induced Type 2 diabetes.

"We are pleased to welcome an elite scientist like Dr. Marth to Burnham and to this collaborative partnership with UCSB in the exciting field of nanomedicine," said Dr. John Reed, Burnham's president and chief executive officer, and professor and Donald Bren Presidential Chair at the institute. "The impact of our collaborative efforts will be far-reaching, not only in terms of advancing the science of nanomedicine, but in terms of economic development opportunities for new company generation and job creation."

Pierre Wiltzius, Worster Dean of Science and professor of physics at UCSB, noted that Marth will play a central role in shaping the future of biomedical research on campus and described him as a "truly stellar biomolecular scientists who merits these prestigious endowed chairs."

"The coupling of biomolecules to nanomaterials and their assembly into nanostructures will produce a wide range of 'smart' devices with an enormous breadth of practical applications, including diagnostics and biosensors, drug screening and delivery, tissue engineering, and much more," Wiltzius added. "The impact of this new field of science, termed 'nanomedicine,' on medicine and life sciences will be hugely transformative, comparable in magnitude to the transition from transistors to silicon chips in the computer sciences."

Larry Coldren, acting dean of UCSB's College of Engineering and Kavli Professor of Optoelectronics and Sensors, described the new center's collaborative opportunities in nanomedicine and systems biology as a "perfect complement" to research underway at UCSB on networked systems approaches to drug development and therapies. "The combination of Jamey Marth's interests in disease mechanisms with our strengths in bioengineering and computational and materials sciences will be highly synergistic, and could well lead to major advances in therapies for grievous human diseases," he said.

Burnham established an affiliation with UCSB in 2006, led by internationally renowned biomedical researcher Erkki Ruoslahti, M.D., Ph.D. Dr. Ruoslahti maintained his primary appointment as Distinguished Professor with Burnham and joined UCSB's Department of Molecular, Cellular, and Developmental Biology as an adjunct Distinguished Professor. This type of collaboration, involving a highly ranked university and a nonprofit, independent research institute, exemplifies the inherent value of interdisciplinary research and the enhanced potential created when two such entities join forces.

"Professor Marth will invigorate interdisciplinary biomedical research at UC Santa Barbara, not only with his own exciting research in the Molecular, Cellular and Developmental Biology Department, but also with expansion of the Burnham Institute at UCSB," said Dennis O. Clegg, co-director of UCSB's Center for Stem Cell Biology and Engineering, and professor and recent past chair of MCDB. "Burnham is one the premier forces in medical research in the world, and expansion of the partnership with UCSB will enable novel approaches to uncover the molecular mechanisms of disease."


'/>"/>

Contact: Eileen Conrad
eileen.conrad@ia.ucsb.edu
805-893-8726
University of California - Santa Barbara
Source:Eurekalert  

Related biology news :

1. Western Groundfish Conference to be held in Santa Cruz on Feb. 4-8
2. UC Santa Barbara has key role in Large Hadron Collider project
3. Rudolfs kin more than just Santas ride
4. The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen
5. Burnham researcher awarded $8 million grant
6. Burnham researchers turn cancer friend into cancer foe
7. The Burnham buzz
8. Burnham researchers discover on switch for cell death signaling mechanism
9. The Burnham Buzz, February 2009
10. Burnham researchers present at 100th AACR Meeting
11. Palm Beach County wants to establish a Max Planck Institute in Florida
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Santa Barbara and Burnham Institute for Medical Research announce director
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... , Jan. 18, 2017 The ... reach USD 92.9 billion by 2025, according to ... Pharmaceutical industry has been adaptive of the function ... early as 2002. Among the services outsourced, clinical ... For instance, Johnson & Johnson was the first ...
(Date:1/19/2017)... , Jan. 18, 2017 Acupath Laboratories, Inc., ... the formation of an Executive Committee that will guide ... John Cucci , a 15-year veteran ... Director of Business Development to Chief Sales Officer ... Cucci served in senior sales leadership roles at several ...
(Date:1/18/2017)... Portland, OR (PRWEB) , ... January 18, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... Altera Cyclone V E FPGA into a compact business-card sized form factor suitable ...
(Date:1/18/2017)... --  Boston Biomedical , an industry leader in the ... pathways, will feature data from two clinical studies for ... Gastrointestinal Cancers Symposium, held from January 19-21, in ... is an orally-administered investigational agent designed to inhibit cancer ... cells (CSCs) possess the property of stemness – the ...
Breaking Biology Technology: